Regenerative biotechnology
Autologous Natural Killer Cells
Autologous Natural Killer cells pretreated with immune checkpoint inhibitors.
Injectable solution of autologous Natural Killer cells pretreated with nivolumab and ipilimumab to activate the innate and adaptive immune response against tumor cells.
Composition
Autologous Natural Killer cells with nivolumab and ipilimumab.
Pharmaceutical form
Injectable solution.
Presentation
Monovette with 4 ml.
Therapeutic Properties
Innate and adaptive immune activation through NK cell cytotoxicity and enhancement of T lymphocytes against tumor cells.
- Activation of autologous NK cells.
- Cytotoxic destruction of tumor cells.
- Blockade of tumor immune evasion.
- Activation of specific T lymphocytes.
- Reduction of tumor growth.
- Increased immunological visibility of the tumor.
- Support in advanced neoplasms.
- Enhancement of sustained antitumor response.
Mechanism of action & Clinical data
NK cells induce tumor apoptosis and, with PD-1 and CTLA-4 blockade, enhance innate and adaptive immune responses.